Literature DB >> 26965018

Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.

D H W Steel1,2, C Parkes3, V T Papastavrou3, P J Avery4, I A El-Ghrably5, M S Habib1, M T Sandinha1, J Smith1, K P Stannard3, D Vaideanu-Collins5, R J Hillier3.   

Abstract

PurposeTo assess the preoperative features of patients with idiopathic macular hole (IMH) and vitreomacular adhesion (VMA) treated with ocriplasmin (OCP) that can predict successful closure.MethodData were prospectively collected on all patients with IMH treated with OCP in three British ophthalmic centres. Several preoperative variables were recorded including the IMH base diameter (BD), minimum linear diameter (MLD), and VMA width measured on spectral domain optical coherence tomography. Several other IMH indices were derived including a 'width factor', defined as the BD minus the MLD in μm. The occurrence of VMA release and hole closure were used as the main outcome measures.ResultsThirty-three patients in total with IMH were treated with OCP. Two patients developed rhegmatogenous retinal detachment and were excluded. The mean age of the remaining 31 patients was 71 years, and 71% were female. VMA release occurred in 19 of the 31 (61%) patients and macular hole closure in 11 (35%). Width factor was the most predictive feature for closure on multivariate analysis. The deviance R(2) was 67% (P<0.001). An IMH with a width factor of <60 μm had a 95% certainty of closure, whereas if >290 μm then there was less than a 5% chance of closure. Neither VMA width nor MLD alone was associated with VMA release or closure.ConclusionsPatients with macular holes where the BD was close in size to the MLD had an improved probability of closure than holes with wider base configurations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26965018      PMCID: PMC4869143          DOI: 10.1038/eye.2016.42

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  24 in total

1.  Nanoscale topographic and biomechanical studies of the human internal limiting membrane.

Authors:  Paul B Henrich; Christophe A Monnier; Willi Halfter; Christos Haritoglou; Rupert W Strauss; Roderick Y H Lim; Marko Loparic
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-29       Impact factor: 4.799

2.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

3.  Comparison of manually corrected retinal thickness measurements from multiple spectral-domain optical coherence tomography instruments.

Authors:  Florian M Heussen; Yanling Ouyang; Emma C McDonnell; Ramsudha Narala; Humberto Ruiz-Garcia; Alexander C Walsh; SriniVas R Sadda
Journal:  Br J Ophthalmol       Date:  2011-07-06       Impact factor: 4.638

4.  Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin.

Authors:  Francis Char DeCroos; Cynthia A Toth; Francisco A Folgar; Stephen Pakola; Sandra S Stinnett; Cynthia S Heydary; Russell Burns; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-21       Impact factor: 4.799

5.  Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.

Authors:  Rishi P Singh; Ang Li; Rumneek Bedi; Sunil Srivastava; Jonathan E Sears; Justis P Ehlers; Andrew P Schachat; Peter K Kaiser
Journal:  Br J Ophthalmol       Date:  2013-12-19       Impact factor: 4.638

6.  Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.

Authors:  Brian T Kim; Stephen G Schwartz; William E Smiddy; Rishi R Doshi; Jaclyn L Kovach; Audina M Berrocal; Andrew A Moshfeghi; Jorge A Fortun
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2013 Jul-Aug       Impact factor: 1.300

7.  Prediction of postoperative visual outcome based on hole configuration by optical coherence tomography in eyes with idiopathic macular holes.

Authors:  Sentaro Kusuhara; Michael F Teraoka Escaño; Shigeki Fujii; Yoriko Nakanishi; Yasushi Tamura; Azusa Nagai; Hiroyuki Yamamoto; Yasutomo Tsukahara; Akira Negi
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

8.  Optical coherence tomography predictive factors for macular hole surgery outcome.

Authors:  J M Ruiz-Moreno; C Staicu; D P Piñero; J Montero; F Lugo; P Amat
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

9.  Movement of the inner retina complex during the development of primary full-thickness macular holes: implications for hypotheses of pathogenesis.

Authors:  Wai H Woon; Denis Greig; Mike D Savage; Mark C T Wilson; Colin A Grant; Bataung Mokete; Fiona Bishop
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-13       Impact factor: 3.117

Review 10.  Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment.

Authors:  D H W Steel; A J Lotery
Journal:  Eye (Lond)       Date:  2013-10       Impact factor: 3.775

View more
  12 in total

1.  Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?

Authors:  Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-28       Impact factor: 3.117

2.  Ocriplasmin - variable efficacy?

Authors:  David H W Steel; David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-04       Impact factor: 3.117

3.  Central mfERG amplitude ratio as a predictor for visual outcome of macular hole surgery.

Authors:  Renata Moreto; Ana Claudia Brancato De Lucca Perches; Felipe Almeida; Rodrigo Jorge; André Messias; Katrin Gekeler
Journal:  Doc Ophthalmol       Date:  2019-09-03       Impact factor: 2.379

4.  Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?

Authors:  Kleanthis Manousaridis; Silvia Peter-Reichart; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-05       Impact factor: 3.117

5.  Macular hole morphology and measurement using an automated three-dimensional image segmentation algorithm.

Authors:  Yunzi Chen; Amar V Nasrulloh; Ian Wilson; Caspar Geenen; Maged Habib; Boguslaw Obara; David H W Steel
Journal:  BMJ Open Ophthalmol       Date:  2020-08-16

6.  Area and volume ratios for prediction of visual outcome in idiopathic macular hole.

Authors:  Xing-Yun Geng; Hui-Qun Wu; Jie-Hui Jiang; Kui Jiang; Jun Zhu; Yi Xu; Jian-Cheng Dong; Zhuang-Zhi Yan
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

7.  Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies.

Authors:  Brian C Joondeph; Paul Willems; Thomas Raber; Luc Duchateau; Joseph Markoff
Journal:  J Ophthalmic Vis Res       Date:  2021-01-20

8.  Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.

Authors:  Arshad M Khanani; Ryan N Constantine; Koenraad H Blot; Benedicte Lescrauwaet; Peter Szurman
Journal:  Acta Ophthalmol       Date:  2020-12-26       Impact factor: 3.761

Review 9.  Ocriplasmin for Treatment of Vitreomacular Traction: An Update.

Authors:  Mohammed Ali Khan; Julia A Haller
Journal:  Ophthalmol Ther       Date:  2016-09-12

10.  OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

Authors:  David H W Steel; Niall Patton; Theodor Stappler; Niral Karia; Hans Hoerauf; Nishal Patel; Joachim Wachtlin; Thomas Raber; Petra Kozma-Wiebe
Journal:  Retina       Date:  2021-02-01       Impact factor: 3.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.